Trial · NCT02656524
Stivarga Real Life Evidence in Hungary
NCT02656524, Completed, Bayer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Stivarga Real Life Evidence in Hungary. Trials, record NCT02656524. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02656524
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Stivarga Real Life Evidence in Hungary
- NCT number
- NCT02656524
- Status
- Completed
- Enrollment
- 400 participants, actual
- Lead sponsor
- Bayer
- Conditions
- Colorectal Neoplasms
- Interventions
- Regorafenib (Stivarga, BAY73-4506)
- First posted
- 2016-01-15
- Last updated
- 2018-02-12
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Length of treatment for each treatment episode | Retrospective analysis of 2 year period | The length of each treatment episode will be calculated based on the duration between the initiation date of a treatment episode and the end date of the same treatment episode |
| Primary | Progression Free Survival (PFS) | Retrospective analysis of 2 year period | PFS will be defined as days between start of the therapy and the date of the medical doctors opinion about progression (confirmed by radiology or clinical assessment) |
| Primary | Overall Survival (OS) | Retrospective analysis of 2 year period | |
| Primary | Number of participants with treatment emergent adverse events as a measure of safety and tolerability | Retrospective analysis of 2 year period | |
| Secondary | Resource utilization per patient | Retrospective analysis of 2 year period | Costs per patient for the reimbursed healthcare service e.g. inpatient care, outpatient visit, emergency departement visit, pharmaceutical dispensing |
| Other | Time to treatment failure (TTF) | Retrospective analysis of 2 year period | Time to treatment failure is defined as days between the first drug delivery to the health care provider and date of treatment discontinuation due to any reason, including death |
| Other | Time to progression (TTP) | Retrospective analysis of 2 year period | Time to progression is defined as days between the first drug delivery to the health care provider and the date of progression defined by the medical doctor |
| Other | Characteristics of patients with better response | Retropsective analysis of 2 year period | Patients with "better response" are defined as receiving more cycles of regorafenib treatment than the median number of cycles (2 cycles). Their distribution is analyzed by KRAS status, by the location of the primary tumour, by age, by prior cancer therapies and by location of metastases. |
| Other | Time frame between the baseline computed tomography and the first drug delivery | Retrospective analysis of 2 year period | Time frame between the date of the baseline computed tomography (CT) and the date of the first drug delivery to the health care provider |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02656524
GET https://conductscience.org/api/trials/v1/NCT02656524/registered